In the fast-paced world of vaccine development, innovation depends on efficiency, flexibility, and scalability. LenioBio is advancing this transformation with ALiCE® (Almost LIving Cell-free Expression)-a state-of-the-art cell-free protein synthesis platform that accelerates and streamlines vaccine development.
Founded in 2016 and headquartered in Düsseldorf, Germany, LenioBio addresses one of drug discovery’s biggest challenges: Rapid and reliable protein production. With ALiCE®, even complex and previously unreachable protein targets are produced in a fraction of the time typically required by cell-based systems.
With its versatile product and service portfolio, LenioBio is uniquely positioned to overcome bottlenecks, speeding the development of both current and next-generation vaccines-from antigen discovery and optimization to virus-like particle development and beyond.